Lupus

PRNewswire/ -- Lupus is a complicated and debilitating autoimmune disease, affecting millions of people across the globe. Yet, lupus drug development lags.

Learn more about the Lupus Foundation of America at [lupus.org](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=2807258090&u=https%3A%2F%2Fwww.lupus.org%2F&a=lupus.org). Anca Askanase](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=1080093699&u=https%3A%2F%2Fwww.lupus.org%2Fleadership%2Fanca-d-askanase-md-mph&a=Dr.+Anca+Askanase). Joan Merrill](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=1501799659&u=https%3A%2F%2Fwww.lupus.org%2Fleadership%2Fjoan-t-merrill-md&a=Dr.+Joan+Merrill) and [Dr. In a new report, " [The ALPHA Project: A Stakeholder Meeting on Lupus Clinical Trial Outcome Measures and the Patient Perspective](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=66342761&u=https%3A%2F%2Flupus.bmj.com%2Fcontent%2F10%2F1%2Fe000901&a=The+ALPHA+Project%3A+A+Stakeholder+Meeting+on+Lupus+Clinical+Trial+Outcome+Measures+and+the+Patient+Perspective)," published in Lupus Science & Medicine, the GAC and other key experts discuss how lupus disease complexity dictates necessary changes to clinical trial outcome measures, including incorporating patient voice and preference, to facilitate drug development progress. [lupus](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=3645379305&u=https%3A%2F%2Fwww.lupus.org%2Fresources%2Fwhat-is-lupus&a=lupus), one of the world's cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact. In 2019, the LFA launched the ALPHA Project, a comprehensive, multi-phase, global consensus initiative aimed at identifying and addressing the most pressing barriers to improving lupus outcomes. [Lupus Foundation of America Rapid Evaluation of Activity in Lupus](https://c212.net/c/link/?t=0&l=en&o=3783384-1&h=2263966424&u=https%3A%2F%2Fwww.lupus.org%2Fimproving-clinical-trials%2Flfareal-system&a=Lupus+Foundation+of+America+Rapid+Evaluation+of+Activity+in+Lupus) measure developed by LFA in concert with [Dr. Only one lupus outcome measure tool includes patient-reported and clinician-reported outcomes, the Costenbader, MD, MPH, report author and Lupus Foundation of America Medical-Scientific Advisory Council Chair and Director of the Lupus Program at Brigham and Women's Hospital. Yet, lupus drug development lags behind that of other rheumatic diseases, likely due to the complexity of the disease. To address the urgent need to develop therapeutic solutions, the 14, 2023 /PRNewswire/ -- Lupus is a complicated and debilitating autoimmune disease, affecting millions of people across the globe.